<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00550537</url>
  </required_header>
  <id_info>
    <org_study_id>VICC-THO-0640</org_study_id>
    <secondary_id>P30CA068485</secondary_id>
    <secondary_id>VU-VICC-THO-0640</secondary_id>
    <secondary_id>VU-VICC-070494</secondary_id>
    <nct_id>NCT00550537</nct_id>
  </id_info>
  <brief_title>Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Feasibility Study Investigating Translational Science in Chemotherapy-Naive Patients With Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) Treated With the EGFR-TKI, Erlotinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tumor tissue, blood, and urine in the laboratory from patients
      receiving erlotinib may help doctors predict how patients will respond to treatment.

      PURPOSE: The phase II trial is studying proteomic profiling to see how well it predicts
      response in patients receiving erlotinib for stage IIIB, stage IV, or recurrent non-small
      cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To define a pre-treatment tumor proteomic profile that predicts response, stable
           disease, or progressive disease in patients with stage IIIB, stage IV, or recurrent
           non-small cell lung cancer treated with erlotinib hydrochloride.

      Secondary

        -  To test and refine a pre-treatment serum proteomic expression pattern that predicts
           response to erlotinib hydrochloride and/or carboplatin and paclitaxel after failing
           treatment with erlotinib hydrochloride.

        -  To test and refine tumor proteomic profiles that predict response to carboplatin and
           paclitaxel after failing treatment with erlotinib hydrochloride.

        -  To analyze individual and pattern(s) of erlotinib hydrochloride-induced genomic and
           proteomic biomarker changes in relation to response or non-response to treatment.

        -  To correlate the efficacy and toxicity of erlotinib hydrochloride with expression of
           EGFR, EGFR pathway, ErbB family, and other related biomarkers.

        -  To determine a set of biomarkers to be evaluated in tumor tissue or surrogate tissues
           prior to treatment with erlotinib hydrochloride to enable patient selection for therapy.

        -  To estimate response rate and progression-free and overall survival of patients treated
           with erlotinib hydrochloride as initial therapy.

        -  To characterize the safety profile of erlotinib hydrochloride in these patients.

      OUTLINE: This is a multicenter study.

      Patients receive oral erlotinib hydrochloride once daily until disease progression.

      At the time of disease progression, patients receive standard chemotherapy comprising
      paclitaxel IV over 3 hours and carboplatin IV over 15-30 minutes on day 1. Patients with
      non-squamous cell non-small cell lung cancer also receive bevacizumab IV over 30-90 minutes
      on day 1. Treatment repeats every 21 days for up to 6 courses.

      Tumor tissue, plasma, serum, and urine samples are collected at baseline for proteomics
      analysis.

      After the completion of study treatment, patients are followed every 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-treatment Tumor Proteomic Profile as a Predictor of Response, Stable Disease, or Progressive Disease</measure>
    <time_frame>End of treatment date</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment Serum Proteomic Expression Pattern as a Predictor of Response to Erlotinib Hydrochloride and/or Carboplatin and Paclitaxel After Failing Treatment With Erlotinib Hydrochloride</measure>
    <time_frame>End of treatment date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Proteomic Profiles as Predictors of Response to Carboplatin and Paclitaxel After Failing Treatment With Erlotinib Hydrochloride</measure>
    <time_frame>End of treatment date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of Individual and Pattern(s) of Erlotinib Hydrochloride-induced Genomic and Proteomic Biomarker Changes in Relation to Response or Non-response to Treatment</measure>
    <time_frame>End of treatment date</time_frame>
    <description>End of treatment date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the Efficacy and Toxicity of Erlotinib Hydrochloride With Expression of EGFR, EGFR Pathway, ErbB Family, and Other Related Biomarkers</measure>
    <time_frame>End of treatment date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of a Set of Biomarkers to be Evaluated in Tumor Tissue or Surrogate Tissues Prior to Treatment With Erlotinib Hydrochloride to Enable Patient Selection for Therapy</measure>
    <time_frame>End of treatment date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate for Erlotinib Initial Therapy in Chemotherapy-naïve Patients With Advanced NSCLC</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Number of patients in each response category, per RECIST v1.1, summarized as follows for target lesion criteria (see RECIST v1.1 for additional details): complete response (CR),disappearance of target lesions; partial response (PR), &gt;=30% decrease in sum of longest diameter of target lesions; progressive disease (PD), &gt;=20% increase in sum of LD of target lesions or appearance of new lesions; stable disease (SD), insufficient change in target lesions or new lesions to qualify as either PD or SD. The response rate is calculated as the percentage of PR+CR among patients assessed for response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) for Erlotinib Initial Therapy in Chemotherapy-naïve Patients With Advanced NSCLC</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>PFS is defined as the time from on erlotinib treatment date to progression or death (whichever comes first) before cross-over to PC or PC+B. For those did not progressed nor died, they were censored at the last follow up (either the off erlotinib treatment date or lost follow up date). The median survival time and 95% confidence interval were estimated using Kaplan-meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Worst-grade Toxicities Per Grade</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>The intensity of the AE will be graded according to the Common Toxicity Criteria (CTC) of the (US) National Cancer Institute (NCI) - Cancer Therapy Evaluation Program (CTEP) [version 3.0 of December 2003] (Appendix B).
Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival for Erlotinib Initial Therapy in Chemotherapy-naïve Patients With Advanced NSCLC</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>The overall survival time is defined as the time from on treatment to death. Patients were censored of they were alive at the last follow up date. The median survival time and its confidence interval were estimated using Kaplan-meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>15 mg/m2 given through a vein for every 3 weeks</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>AUC = 6 given through a vein on day 1 of each cycle.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>150 mg taken by mouth daily</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>200 mg/m2 given through a vein on day 1 of each cycle.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <description>Blood and tissue collection.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
    <description>Blood and tissue collection.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>proteomic profiling</intervention_name>
    <description>Blood and tissue collection.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Blood and tissue collection.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed non-small cell lung cancer (NSCLC), meeting 1 of the
             following criteria:

               -  Stage IIIB (with pleural effusion) or stage IV disease

               -  Recurrent disease after prior surgery

          -  Measurable or evaluable disease is desirable but not required

          -  No untreated symptomatic brain metastases

               -  Patients who are neurologically unstable despite radiotherapy for the brain
                  metastases are not eligible

               -  No requirement for steroids to control neurological symptoms

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  ANC ≥ 1,500/mm³

          -  Hemoglobin ≥ 9 g/dL

          -  Platelet count ≥ 100,000/mm³

          -  Creatinine ≤ 2.0 mg/dL

          -  Total bilirubin ≤ 1.5 mg/dL

          -  Normal hemostasis by history

          -  PT/PTT within 0.5 seconds of normal range

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Willing to undergo biopsy procedures

          -  No known severe hypersensitivity to erlotinib hydrochloride or any of the excipients
             of this product

          -  No other concurrent malignancies or malignancies diagnosed within the past 5 years,
             except basal cell carcinoma or cervical cancer in situ

          -  No significant cardiac disease, including any of the following:

               -  NYHA class III or IV heart disease

               -  Uncontrolled dysrhythmia

               -  Myocardial infarction within the past 6 months

          -  No evidence of clinically active interstitial lung disease

               -  Chronic stable radiographic changes that are asymptomatic allowed

          -  No evidence of any other severe or uncontrolled systemic disease (e.g., unstable or
             uncompensated respiratory, cardiac, hepatic, or renal disease)

          -  No evidence of any other significant clinical disorder or laboratory finding that
             makes it undesirable for the patient to participate in the trial

          -  No uncontrolled hypertension

               -  Blood pressure must be ≤ 150/90 mmHg on a stable antihypertensive regimen

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 6 months since prior adjuvant chemotherapy

          -  No unresolved chronic toxicity &gt; CTC grade 2 from prior anticancer therapy (except
             alopecia)

          -  More than 30 days since prior non-approved or investigational drugs

          -  No prior chemotherapy for advanced NSCLC

          -  No concurrent phenytoin, carbamazepine, rifampin, barbiturates, or St. John's wort

          -  No concurrent administration of other drugs known to inhibit EGFR

          -  No other concurrent anti-neoplastic or anti-tumor agents, including chemotherapy,
             radiotherapy, immunotherapy, or hormonal anticancer therapy

          -  No other concurrent investigational agents

          -  Concurrent cardioprotective doses of aspirin, as recommended by the physician, for
             cardiovascular disease allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Carbone, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida Shands Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center - Cool Springs</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center at Franklin</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2007</study_first_submitted>
  <study_first_submitted_qc>October 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2007</study_first_posted>
  <results_first_submitted>March 14, 2017</results_first_submitted>
  <results_first_submitted_qc>March 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2017</results_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Leora Horn, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>adenosquamous cell lung cancer</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period for this trial was October 2007 to July 2011. Participants were recruited at Vanderbilt Medical Center, Emory University, M.D. Anderson Cancer Center, University of Florida - Gainesville.</recruitment_details>
      <pre_assignment_details>10 participants were consented to participate in this trial, but were determined to be ineligible; 3 participants withdrew from the study prior to beginning treatment; 1 participant progressed before beginning treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.
bevacizumab: 15 mg/m2 given through a vein for every 3 weeks
carboplatin: AUC = 6 given through a vein on day 1 of each cycle.
erlotinib hydrochloride: 150 mg taken by mouth daily
paclitaxel: 200 mg/m2 given through a vein on day 1 of each cycle.
gene expression analysis: Blood and tissue collection.
protein expression analysis: Blood and tissue collection.
proteomic profiling: Blood and tissue collection.
laboratory biomarker analysis: Blood and tissue collection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression before</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change in treatment plan</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other complicating ilness</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Declining performance status</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treated closer to home</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.
bevacizumab: 15 mg/m2 given through a vein for every 3 weeks
carboplatin: AUC = 6 given through a vein on day 1 of each cycle.
erlotinib hydrochloride: 150 mg taken by mouth daily
paclitaxel: 200 mg/m2 given through a vein on day 1 of each cycle.
gene expression analysis: Blood and tissue collection.
protein expression analysis: Blood and tissue collection.
proteomic profiling: Blood and tissue collection.
laboratory biomarker analysis: Blood and tissue collection.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.9" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pre-treatment Tumor Proteomic Profile as a Predictor of Response, Stable Disease, or Progressive Disease</title>
        <time_frame>End of treatment date</time_frame>
        <population>Lab data was lost by the collaborating institution, Colorado.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.
bevacizumab: 15 mg/m2 given through a vein for every 3 weeks
carboplatin: AUC = 6 given through a vein on day 1 of each cycle.
erlotinib hydrochloride: 150 mg taken by mouth daily
paclitaxel: 200 mg/m2 given through a vein on day 1 of each cycle.
gene expression analysis: Blood and tissue collection.
protein expression analysis: Blood and tissue collection.
proteomic profiling: Blood and tissue collection.
laboratory biomarker analysis: Blood and tissue collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-treatment Tumor Proteomic Profile as a Predictor of Response, Stable Disease, or Progressive Disease</title>
          <population>Lab data was lost by the collaborating institution, Colorado.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-treatment Serum Proteomic Expression Pattern as a Predictor of Response to Erlotinib Hydrochloride and/or Carboplatin and Paclitaxel After Failing Treatment With Erlotinib Hydrochloride</title>
        <time_frame>End of treatment date</time_frame>
        <population>Lab data was lost by the collaborating institution, Colorado.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.
bevacizumab: 15 mg/m2 given through a vein for every 3 weeks
carboplatin: AUC = 6 given through a vein on day 1 of each cycle.
erlotinib hydrochloride: 150 mg taken by mouth daily
paclitaxel: 200 mg/m2 given through a vein on day 1 of each cycle.
gene expression analysis: Blood and tissue collection.
protein expression analysis: Blood and tissue collection.
proteomic profiling: Blood and tissue collection.
laboratory biomarker analysis: Blood and tissue collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-treatment Serum Proteomic Expression Pattern as a Predictor of Response to Erlotinib Hydrochloride and/or Carboplatin and Paclitaxel After Failing Treatment With Erlotinib Hydrochloride</title>
          <population>Lab data was lost by the collaborating institution, Colorado.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Proteomic Profiles as Predictors of Response to Carboplatin and Paclitaxel After Failing Treatment With Erlotinib Hydrochloride</title>
        <time_frame>End of treatment date</time_frame>
        <population>Lab data was lost by the collaborating institution, Colorado.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.
bevacizumab: 15 mg/m2 given through a vein for every 3 weeks
carboplatin: AUC = 6 given through a vein on day 1 of each cycle.
erlotinib hydrochloride: 150 mg taken by mouth daily
paclitaxel: 200 mg/m2 given through a vein on day 1 of each cycle.
gene expression analysis: Blood and tissue collection.
protein expression analysis: Blood and tissue collection.
proteomic profiling: Blood and tissue collection.
laboratory biomarker analysis: Blood and tissue collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Proteomic Profiles as Predictors of Response to Carboplatin and Paclitaxel After Failing Treatment With Erlotinib Hydrochloride</title>
          <population>Lab data was lost by the collaborating institution, Colorado.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of Individual and Pattern(s) of Erlotinib Hydrochloride-induced Genomic and Proteomic Biomarker Changes in Relation to Response or Non-response to Treatment</title>
        <description>End of treatment date</description>
        <time_frame>End of treatment date</time_frame>
        <population>Lab data was lost by the collaborating institution, Colorado.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.
bevacizumab: 15 mg/m2 given through a vein for every 3 weeks
carboplatin: AUC = 6 given through a vein on day 1 of each cycle.
erlotinib hydrochloride: 150 mg taken by mouth daily
paclitaxel: 200 mg/m2 given through a vein on day 1 of each cycle.
gene expression analysis: Blood and tissue collection.
protein expression analysis: Blood and tissue collection.
proteomic profiling: Blood and tissue collection.
laboratory biomarker analysis: Blood and tissue collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Individual and Pattern(s) of Erlotinib Hydrochloride-induced Genomic and Proteomic Biomarker Changes in Relation to Response or Non-response to Treatment</title>
          <description>End of treatment date</description>
          <population>Lab data was lost by the collaborating institution, Colorado.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of the Efficacy and Toxicity of Erlotinib Hydrochloride With Expression of EGFR, EGFR Pathway, ErbB Family, and Other Related Biomarkers</title>
        <time_frame>End of treatment date</time_frame>
        <population>Lab data was lost by the collaborating institution, Colorado.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.
bevacizumab: 15 mg/m2 given through a vein for every 3 weeks
carboplatin: AUC = 6 given through a vein on day 1 of each cycle.
erlotinib hydrochloride: 150 mg taken by mouth daily
paclitaxel: 200 mg/m2 given through a vein on day 1 of each cycle.
gene expression analysis: Blood and tissue collection.
protein expression analysis: Blood and tissue collection.
proteomic profiling: Blood and tissue collection.
laboratory biomarker analysis: Blood and tissue collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of the Efficacy and Toxicity of Erlotinib Hydrochloride With Expression of EGFR, EGFR Pathway, ErbB Family, and Other Related Biomarkers</title>
          <population>Lab data was lost by the collaborating institution, Colorado.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determination of a Set of Biomarkers to be Evaluated in Tumor Tissue or Surrogate Tissues Prior to Treatment With Erlotinib Hydrochloride to Enable Patient Selection for Therapy</title>
        <time_frame>End of treatment date</time_frame>
        <population>Lab data was lost by the collaborating institution, Colorado.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.
bevacizumab: 15 mg/m2 given through a vein for every 3 weeks
carboplatin: AUC = 6 given through a vein on day 1 of each cycle.
erlotinib hydrochloride: 150 mg taken by mouth daily
paclitaxel: 200 mg/m2 given through a vein on day 1 of each cycle.
gene expression analysis: Blood and tissue collection.
protein expression analysis: Blood and tissue collection.
proteomic profiling: Blood and tissue collection.
laboratory biomarker analysis: Blood and tissue collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Determination of a Set of Biomarkers to be Evaluated in Tumor Tissue or Surrogate Tissues Prior to Treatment With Erlotinib Hydrochloride to Enable Patient Selection for Therapy</title>
          <population>Lab data was lost by the collaborating institution, Colorado.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate for Erlotinib Initial Therapy in Chemotherapy-naïve Patients With Advanced NSCLC</title>
        <description>Number of patients in each response category, per RECIST v1.1, summarized as follows for target lesion criteria (see RECIST v1.1 for additional details): complete response (CR),disappearance of target lesions; partial response (PR), &gt;=30% decrease in sum of longest diameter of target lesions; progressive disease (PD), &gt;=20% increase in sum of LD of target lesions or appearance of new lesions; stable disease (SD), insufficient change in target lesions or new lesions to qualify as either PD or SD. The response rate is calculated as the percentage of PR+CR among patients assessed for response.</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
        <population>Total 116 participants, 11 not assessed and 4 not evaluable. 101 assessed for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients on Erlotinib Segament</title>
            <description>Erlotinib followed by paclitaxel + carboplatin (PC) or paclitaxel + carboplatin + bevacizumab (PC+B) in non-squamous cell at the time disease progression.
bevacizumab: 15 mg/m2 given through a vein for every 3 weeks
carboplatin: AUC = 6 given through a vein on day 1 of each cycle.
erlotinib hydrochloride: 150 mg taken by mouth daily
paclitaxel: 200 mg/m2 given through a vein on day 1 of each cycle.
gene expression analysis: Blood and tissue collection.
protein expression analysis: Blood and tissue collection.
proteomic profiling: Blood and tissue collection.
laboratory biomarker analysis: Blood and tissue collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate for Erlotinib Initial Therapy in Chemotherapy-naïve Patients With Advanced NSCLC</title>
          <description>Number of patients in each response category, per RECIST v1.1, summarized as follows for target lesion criteria (see RECIST v1.1 for additional details): complete response (CR),disappearance of target lesions; partial response (PR), &gt;=30% decrease in sum of longest diameter of target lesions; progressive disease (PD), &gt;=20% increase in sum of LD of target lesions or appearance of new lesions; stable disease (SD), insufficient change in target lesions or new lesions to qualify as either PD or SD. The response rate is calculated as the percentage of PR+CR among patients assessed for response.</description>
          <population>Total 116 participants, 11 not assessed and 4 not evaluable. 101 assessed for response.</population>
          <units>percentage of patients assessed</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="12.4" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) for Erlotinib Initial Therapy in Chemotherapy-naïve Patients With Advanced NSCLC</title>
        <description>PFS is defined as the time from on erlotinib treatment date to progression or death (whichever comes first) before cross-over to PC or PC+B. For those did not progressed nor died, they were censored at the last follow up (either the off erlotinib treatment date or lost follow up date). The median survival time and 95% confidence interval were estimated using Kaplan-meier method.</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
        <population>Total 116 participants. One patient was excluded due to death before erlotinib treatment. Total 115 patients were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients on Erlotinib Segament</title>
            <description>Erlotinib followed by paclitaxel + carboplatin (PC) or paclitaxel + carboplatin + bevacizumab (PC+B) in non-squamous cell at the time disease progression.
bevacizumab: 15 mg/m2 given through a vein for every 3 weeks
carboplatin: AUC = 6 given through a vein on day 1 of each cycle.
erlotinib hydrochloride: 150 mg taken by mouth daily
paclitaxel: 200 mg/m2 given through a vein on day 1 of each cycle.
gene expression analysis: Blood and tissue collection.
protein expression analysis: Blood and tissue collection.
proteomic profiling: Blood and tissue collection.
laboratory biomarker analysis: Blood and tissue collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) for Erlotinib Initial Therapy in Chemotherapy-naïve Patients With Advanced NSCLC</title>
          <description>PFS is defined as the time from on erlotinib treatment date to progression or death (whichever comes first) before cross-over to PC or PC+B. For those did not progressed nor died, they were censored at the last follow up (either the off erlotinib treatment date or lost follow up date). The median survival time and 95% confidence interval were estimated using Kaplan-meier method.</description>
          <population>Total 116 participants. One patient was excluded due to death before erlotinib treatment. Total 115 patients were included in the analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" lower_limit="2.70" upper_limit="4.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Worst-grade Toxicities Per Grade</title>
        <description>The intensity of the AE will be graded according to the Common Toxicity Criteria (CTC) of the (US) National Cancer Institute (NCI) – Cancer Therapy Evaluation Program (CTEP) [version 3.0 of December 2003] (Appendix B).
Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
        <population>116 paticipants, one patient was excluded due to death before any treatment. All patients who received erlotinib treatment and experienced an Adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib Segament</title>
            <description>Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.
bevacizumab: 15 mg/m2 given through a vein for every 3 weeks
carboplatin: AUC = 6 given through a vein on day 1 of each cycle.
erlotinib hydrochloride: 150 mg taken by mouth daily
paclitaxel: 200 mg/m2 given through a vein on day 1 of each cycle.
gene expression analysis: Blood and tissue collection.
protein expression analysis: Blood and tissue collection.
proteomic profiling: Blood and tissue collection.
laboratory biomarker analysis: Blood and tissue collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Worst-grade Toxicities Per Grade</title>
          <description>The intensity of the AE will be graded according to the Common Toxicity Criteria (CTC) of the (US) National Cancer Institute (NCI) – Cancer Therapy Evaluation Program (CTEP) [version 3.0 of December 2003] (Appendix B).
Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE</description>
          <population>116 paticipants, one patient was excluded due to death before any treatment. All patients who received erlotinib treatment and experienced an Adverse events.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>worst-grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>worst-grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>worst-grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>worst-grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival for Erlotinib Initial Therapy in Chemotherapy-naïve Patients With Advanced NSCLC</title>
        <description>The overall survival time is defined as the time from on treatment to death. Patients were censored of they were alive at the last follow up date. The median survival time and its confidence interval were estimated using Kaplan-meier method.</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
        <population>Total 116 participants. One patient was excluded due to death before any treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib Followed by PC</title>
            <description>Erlotinib followed by paclitaxel + carboplatin (PC) or paclitaxel + carboplatin + bevacizumab (PC+B) in non-squamous cell at the time disease progression.
bevacizumab: 15 mg/m2 given through a vein for every 3 weeks
carboplatin: AUC = 6 given through a vein on day 1 of each cycle.
erlotinib hydrochloride: 150 mg taken by mouth daily
paclitaxel: 200 mg/m2 given through a vein on day 1 of each cycle.
gene expression analysis: Blood and tissue collection.
protein expression analysis: Blood and tissue collection.
proteomic profiling: Blood and tissue collection.
laboratory biomarker analysis: Blood and tissue collection.</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib Followed by PC+B</title>
            <description>Erlotinib followed by paclitaxel + carboplatin (PC) or paclitaxel + carboplatin + bevacizumab (PC+B) in non-squamous cell at the time disease progression.
bevacizumab: 15 mg/m2 given through a vein for every 3 weeks
carboplatin: AUC = 6 given through a vein on day 1 of each cycle.
erlotinib hydrochloride: 150 mg taken by mouth daily
paclitaxel: 200 mg/m2 given through a vein on day 1 of each cycle.
gene expression analysis: Blood and tissue collection.
protein expression analysis: Blood and tissue collection.
proteomic profiling: Blood and tissue collection.
laboratory biomarker analysis: Blood and tissue collection.</description>
          </group>
          <group group_id="O3">
            <title>Erlotinib</title>
            <description>Erlotinib followed by paclitaxel + carboplatin (PC) or paclitaxel + carboplatin + bevacizumab (PC+B) in non-squamous cell at the time disease progression.
bevacizumab: 15 mg/m2 given through a vein for every 3 weeks
carboplatin: AUC = 6 given through a vein on day 1 of each cycle.
erlotinib hydrochloride: 150 mg taken by mouth daily
paclitaxel: 200 mg/m2 given through a vein on day 1 of each cycle.
gene expression analysis: Blood and tissue collection.
protein expression analysis: Blood and tissue collection.
proteomic profiling: Blood and tissue collection.
laboratory biomarker analysis: Blood and tissue collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival for Erlotinib Initial Therapy in Chemotherapy-naïve Patients With Advanced NSCLC</title>
          <description>The overall survival time is defined as the time from on treatment to death. Patients were censored of they were alive at the last follow up date. The median survival time and its confidence interval were estimated using Kaplan-meier method.</description>
          <population>Total 116 participants. One patient was excluded due to death before any treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.53" lower_limit="6.94" upper_limit="19.10"/>
                    <measurement group_id="O2" value="17.23" lower_limit="8.19" upper_limit="30.20"/>
                    <measurement group_id="O3" value="6.08" lower_limit="3.98" upper_limit="12.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were evaluated for adverse events at each study visit for the duration of their participation in the study and for 30 days after the discontinuation of Tarceva. After discontinuation from treatment, patients are followed up for all existing and new AEs for 30 calendar days after the last dose of study drug. All new AEs occurring during that period are recorded and followed to resolution when possible.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.
bevacizumab: 15 mg/m2 given through a vein for every 3 weeks
carboplatin: AUC = 6 given through a vein on day 1 of each cycle.
erlotinib hydrochloride: 150 mg taken by mouth daily
paclitaxel: 200 mg/m2 given through a vein on day 1 of each cycle.
gene expression analysis: Blood and tissue collection.
protein expression analysis: Blood and tissue collection.
proteomic profiling: Blood and tissue collection.
laboratory biomarker analysis: Blood and tissue collection.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI-CTCAE version 3.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (urinary tract)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Infection (pharynx)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Infection (port)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Pulmonary (other)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>iatrogenic pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>worsening pneumothorax and subcutaneous emphysema.</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash (allergy)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI-CTCAE version 3.</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="59" subjects_affected="34" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="19" subjects_affected="11" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Visual alteration</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="96" subjects_affected="59" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="69" subjects_affected="42" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="25" subjects_affected="18" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="105" subjects_affected="60" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="39" subjects_affected="29" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Edema, limb</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="43" subjects_affected="33" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="59" subjects_affected="31" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="51" subjects_affected="27" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Serum glutamic pyruvic transaminase</sub_title>
                <counts group_id="E1" events="41" subjects_affected="23" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Alkaline phosphase</sub_title>
                <counts group_id="E1" events="30" subjects_affected="22" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" events="37" subjects_affected="12" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Magnesium, serum low</sub_title>
                <counts group_id="E1" events="22" subjects_affected="14" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Albumin, serum low</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Potassium, serum low</sub_title>
                <counts group_id="E1" events="19" subjects_affected="11" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="35" subjects_affected="24" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="19" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Limb pain</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Sensory alteration</sub_title>
                <counts group_id="E1" events="38" subjects_affected="25" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration, depression</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Check pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="54" subjects_affected="35" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="43" subjects_affected="31" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reactions</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Pulmonary (other)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Hemorrhage, nose</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Allergic Rhinitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash (acne/acneiform)</sub_title>
                <counts group_id="E1" events="94" subjects_affected="55" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Rash (desquamation)</sub_title>
                <counts group_id="E1" events="76" subjects_affected="40" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="35" subjects_affected="31" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="30" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin (other)</sub_title>
                <counts group_id="E1" events="35" subjects_affected="21" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Leora Horn, Principal Investigator</name_or_title>
      <organization>Vanderbilt-Ingram Cancer Center</organization>
      <email>leora.horn@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

